Dcgi Approves Biological Es 14 Valent Pneumococcal Conjugate Vaccine
Biological E. Limited (Be), A Hyderabad-Based Pharmaceutical And Vaccine Company, Announced That Its 14-Valent Paediatric Pneumococcal Conjugate Vaccine, (Investigational Pneumococcal Polysaccharide Conjugate Vaccine Pcv14) Against S. Pneumoniae Infection Received Approval From The Drugs Controller General Of India (Dcgi) For Manufacture And Commercialisation In India. Pcv14 May Be Administered To Infants 6, 10 And 14 Weeks Of Age In 3 Doses. Streptococcus Pneumoniae Infection Remains One Of The Leading Causes Of Death Among Children Under The Age Of Five In India And In Developing Countries. Be'S Pcv14 Vaccine Will Help Prevent Invasive Pneumococcal Infection And Save Millions Of Lives Worldwide. Be
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!